Aditxt raises $4.2M in private placement of convertible preferred and warrants
Aditxt, Inc.
- Gross proceeds $4.2M from sale of 4,186 Series C-1 convertible preferred shares, 4,186 Series D-1 voting preferred shares, and warrants for ~1.6M common shares.
- Series C-1 convertible at $2.595/share; warrants exercisable at $2.47/share for 5 years, beginning 6 months after issuance.
- Company to use $1.0M of net proceeds for merger obligations with Evofem Biosciences; remainder for working capital.
- Placement agent Dawson James receives 7% cash fee and warrants for 5% of securities sold.
- Private placement expected to close on or about May 6, 2024.